The estimated Net Worth of John Valliant is at least $9.3 Million dollars as of 25 April 2022. Dr Valliant owns over 8,694 units of Fusion Pharmaceuticals stock worth over $6,856,068 and over the last 4 years he sold FUSN stock worth over $1,599,755. In addition, he makes $845,495 as Founder and CEO & Director at Fusion Pharmaceuticals.
Sign up
Dr Valliant FUSN stock SEC Form 4 insiders trading
Dr has made over 16 trades of the Fusion Pharmaceuticals stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 8,694 units of FUSN stock worth $52,512 on 25 April 2022.
The largest trade he's ever made was selling 47,502 units of Fusion Pharmaceuticals stock on 15 February 2022 worth over $383,816. On average, Dr trades about 9,718 units every 3 days since 2020. As of 25 April 2022 he still owns at least 318,147 units of Fusion Pharmaceuticals stock.
You can see the complete history of Dr Valliant stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. John F. Valliant biography
Dr. John F. Valliant is the Founder, CEO & Director at Fusion Pharmaceuticals.
What is the salary of Dr Valliant?
As the Founder and CEO & Director of Fusion Pharmaceuticals, the total compensation of Dr Valliant at Fusion Pharmaceuticals is $845,495. There are no executives at Fusion Pharmaceuticals getting paid more.
How old is Dr Valliant?
Dr Valliant is 51, he's been the Founder and CEO & Director of Fusion Pharmaceuticals since . There are 4 older and 2 younger executives at Fusion Pharmaceuticals. The oldest executive at Fusion Pharmaceuticals Inc. is Dr. James J. O'Leary, 56, who is the Chief Medical Officer.
What's Dr Valliant's mailing address?
John's mailing address filed with the SEC is C/O FUSION PHARMACEUTICALS INC., TWO INTERNATIONAL PLACE, SUITE 2310, BOSTON, MA, 02110.
Insiders trading at Fusion Pharmaceuticals
Over the last 4 years, insiders at Fusion Pharmaceuticals have traded over $1,703,181 worth of Fusion Pharmaceuticals stock and bought 2,415,900 units worth $40,298,362 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Street Partners Llc Adams, and & Johnson Johnson & Johnson.... On average, Fusion Pharmaceuticals executives and independent directors trade stock every 28 days with the average trade being worth of $2,030,355. The most recent stock trade was executed by Steven Gannon on 11 August 2022, trading 44,400 units of FUSN stock currently worth $90,132.
What does Fusion Pharmaceuticals do?
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
What does Fusion Pharmaceuticals's logo look like?
Complete history of Dr Valliant stock trades at Fusion Pharmaceuticals
Fusion Pharmaceuticals executives and stock owners
Fusion Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Dr. John F. Valliant,
Founder, CEO & Director -
John J. Crowley CPA,
Chief Financial Officer -
Dr. Eric Burak Ph.D.,
Chief Technology Officer -
Dr. James J. O'Leary,
Chief Medical Officer -
Dr. Eric Burak,
Chief Scientific Officer -
Eric S. Hoffman Ph.D.,
Sr. VP of Bus. Devel. -
Dr. Isabelle Dussault Ph.D.,
Sr. VP of Research -
Dr. Christopher Paul Leamon Ph.D.,
Chief Scientific Officer -
Mohit Rawat,
Pres & Chief Bus. Officer -
Dr. Marc Schwabish,
SVP of Bus. Devel. and US Operations -
Maria D. Stahl,
Chief Legal Officer -
Amanda Cray,
Sr. Director of Investor Relations & Corp. Communications -
Lynn Wick,
Exec. Director of Fin. & Operations -
Group Holdings (Sbs) Adviso...,
-
Johan Christenson,
Director -
Vii, L.P.Health Cap Vii Gp ...,
-
Heather Preston,
Director -
Street Partners Llc Adams,
10% owner -
James J O'leary,
Chief Medical Officer -
Chau Quang Khuong,
Director -
Advisors Llc Orbi Med Capit...,
-
& Johnson Johnson & Johnson...,
-
Steven Gannon,
-
Teresa Marie Bitetti,
-
Jeremy Bender,
-
Pablo J Cagnoni,
-
Donald A Bergstrom,
-
Christopher P Leamon,
Chief Scientific Officer -
Mohit Rawat,
President & CBO -
David D. Meek,
-
Dmitri Bobilev,
Chief Medical Officer -
Eric Burak,
Chief Technology Officer -
John J Crowley,
Chief Financial Officer -
John Valliant,
Chief Executive Officer -
Philina Lee,
-
Barbara Gayle Duncan,